The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Guselkumab Promising to Slow Joint Damage in Patients with Psoriatic Arthritis

Guselkumab Promising to Slow Joint Damage in Patients with Psoriatic Arthritis

June 29, 2021 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Guselkumab treatment inhibits disease activity and improves axial symptoms in adults with active psoriatic arthritis (PsA) through two years, according to data presented by Philip J. Mease, MD, at the American Academy of Dermatology’s Virtual Meeting Experience 2021, held April 23–25. In this study, patients with moderate to severe plaque psoriasis also experienced complete skin clearance.1

You Might Also Like
  • Guselkumab Promising for Psoriatic Arthritis with Axial Symptoms
  • Secukinumab Inhibits Structural Joint Damage in Active PsA
  • Guselkumab Promising in Patients with PsA
Explore This Issue
August 2021
Also By This Author
  • Study Compares Ixekizumab with Ustekinumab for the Treatment of Nail Psoriasis

The DISCOVER-2 study (NCT03158285) was a randomized, double-blind, multicenter, phase 3 trial that evaluated the efficacy and safety of guselkumab for two years in patients with active PsA who were biologic naive (n=739). The study included a six-week screening phase followed by a blinded, active treatment phase of approximately 100 weeks, which was divided into a placebo-controlled period from week 0 to week 24 and an active treatment period from weeks 24–100.2

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Patients were randomized to receive 100 mg of guselkumab either every four or eight weeks for two years, or to receive 24 weeks of placebo with crossover to guselkumab every four weeks at week 24 through two years. A safety follow-up phase occurred 12 weeks after the last administration of guselkumab.

Findings

The researchers found patients with active PsA taking guselkumab demonstrated continued skin clearance and joint symptom relief, with no new safety signals after two years (112 weeks), results that had manifested both at 24 weeks and one year. Treatment efficacy, related to physical function and physical aspects of health-related quality of life, was originally demonstrated at week 24 and continued through week 100.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The results showed 56% of patients who received guselkumab every four weeks and 55% of patients who received guselkumab every eight weeks achieved at least a 50% improvement in ACR score.

Additionally, a statistically significant inhibition of radiographic progression of joint damage as measured by the modified van der Heijde-Sharp score for PsA was seen at week 24 in patients who received guselkumab every four weeks. Change in total modified van der Heijde- Sharp score for PsA score is defined by a change of score from baseline. This score combines erosion and joint space narrowing scores derived from joint radiographs of the hands and feet. (Note: Guselkumab is not currently approved in the U.S. as a treatment to inhibit structural damage.)

Patients who received guselkumab every eight weeks had less radiographic progression of joint damage than patients who received placebo, but that result was not statistically significant. From weeks 52–100, low rates of radiographic progression of joint damage were seen in patients treated with guselkumab. In the patients who originally received placebo and crossed into the guselkumab-treatment group at week 24, improvements in radiographic progression of joint damage were seen through year two.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Drug Updates Tagged With: PsA Resource Center, Psoriatic ArthritisIssue: August 2021

You Might Also Like:
  • Guselkumab Promising for Psoriatic Arthritis with Axial Symptoms
  • Secukinumab Inhibits Structural Joint Damage in Active PsA
  • Guselkumab Promising in Patients with PsA
  • Guselkumab Improves Active Psoriatic Arthritis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.